Combination glaucoma drop moves toward approval

Article

A preservative-free IOP-lowering eye drop that is a combination of tafluprost and timolol (Taptiqom, Santen) is seeking national licences in European countries after a positive decentralized procedure and a final assessment report from reference member state Germany, the Federal Institute for Drugs and Medical Devices of Germany, and agreement by concerned member states that the fixed-dose product is approvable.

A preservative-free IOP-lowering eye drop that is a combination of tafluprost and timolol (Taptiqom, Santen) is seeking national licences in European countries after a positive decentralized procedure and a final assessment report from reference member state Germany, the Federal Institute for Drugs and Medical Devices of Germany, and agreement by concerned member states that the fixed-dose product is approvable.

The drug, co-developed by Santen and Asahi Glass Co., comes in single-dose containers with 15 µg/mL of the prostaglandin tafluprost and 5 mg/mL of the beta blocker timolol. These two components lower IOP by complementary mechanisms of action, according to Santen, and the combined effect results in additional IOP reduction compared with either compound alone. The drop will be indicated for the reduction of IOP in adults who have open-angle glaucoma or ocular hypertension that has been insufficiently responsive to topical monotherapy.

Santen said it will work to make the drug available as soon as possible. For more detailed information on this news click here.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.